Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 3/20 | 0.46 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.46 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14499819 | 1.00 | SLC6A12 (0.46) | SLC6A12SLC6A11SLC6A13TSHRBRD4 | |
| SCHEMBL5639358 | 1.00 | SLC6A12 (0.46) | SLC6A12SLC6A11SLC6A13TSHRBRD4 | |
| SCHEMBL5638542 | 0.91 | TSHR (0.46) | TSHRBRD4HSD17B10MGAMGAA | |
| SCHEMBL5638546 | 0.91 | TSHR (0.46) | TSHRBRD4HSD17B10MGAMGAA | |
| SCHEMBL14499820 | 0.91 | TSHR (0.46) | TSHRBRD4HSD17B10MGAMGAA | |
| SCHEMBL18257698 | 0.83 | TSHR (0.39) | TSHRBRD4HSD17B10MGAMGAA | |
| SCHEMBL8177080 | 0.82 | SLC6A12 (0.38) | SLC6A12SLC6A11SLC6A13TSHRBRD4 | |
| SCHEMBL31615208 | 0.82 | SLC6A12 (0.38) | SLC6A12SLC6A11SLC6A13TSHRBRD4 | |
| SCHEMBL528624 | 0.81 | TSHR (0.44) | TSHRBRD4HSD17B10MGAMGAA | |
| SCHEMBL7813782 | 0.81 | SLC6A12 (0.65) | SLC6A12SLC6A11SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | SLC6A12 477/4885SLC6A11 179/4885SLC6A13 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.